Infectious Diseases, 5601 Fishers Lane, Rockville, MD 20852; tel. 301–496–2644. A signed Confidential Disclosure Agreement will be required to receive copies of unpublished patent applications.

SUPPLEMENTARY INFORMATION: Technology descriptions follows.

Compositions and Methods for Detecting Loa Loa

Description of Technology: Loa loa is a filarial nematode estimated to infect 3–13 million people in Central and Western Africa. In parts of Africa, mass administration of ivermectin is common for onchocerciasis and lymphatic filariasis control. However, some individuals infected with Loa loa microfilariae in high densities are known to experience post-ivermectin severe adverse events, such as encephalopathy, coma, or even death. Therefore, diagnostic tools that can accurately identify and differentiate *Loa loa* microfilariae from other filarial infections are needed. Microscopic evaluation of blood samples is the only current diagnostic method used to detect *Loa loa* microfilaremia in endemic areas, and is impractical for widespread screening. Molecular based assays are useful and are quantitative, but require the use of sophisticated instrumentation.

The inventors analyzed samples from *Loa loa* infected patients and uninfected controls, and have identified *Loa loa* microfilaria-specific antigens. The pending application claims a variety of means of detecting these antigens.

This technology is available for licensing for commercial development in accordance with 35 U.S.C. 209 and 37 CFR part 404, as well as for further development and evaluation under a research collaboration.

Potential Commercial Applications:

- Diagnostics

Competitive Advantages:

- Highly specific to *Loa loa* microfilariae
- Highly sensitive
- Both diagnostic and quantitative
- Works with blood, urine, or saliva sample

Development Stage:

- Pre-Clinical

Inventors: Thomas B. Nutman, NIAID, NIH; Sasisekhar Bennuru, NIAID, NIH; and Papa Makhtar Drame, NIAID, NIH.

Publications: Drame, Papa, et al. 2016. Identification and Validation of Loa loa Microfilaria-Specific Biomarkers: A Rational Design Approach Using Proteomics and Novel Immunoassays. *mBio,* vol. 7 no. 1 e02132–15.

Intellectual Property: HHS Reference No. E–140–2015/0—US Provisional Patent Application No. 62/153,654 filed April 28, 2015; PCT Patent Application No. PCT/US2016/029673 filed April 28, 2016.

Licensing Contact: James M. Robinson, 301–761–7542; *James.Robinson4@nih.gov.*

Collaborative Research Opportunity: The Technology Transfer and Intellectual Property Office (TTIPO) is seeking parties interested in collaborative research to further develop, evaluate or commercialize a diagnostic means for detecting *Loa loa* microfilaria-specific antigens. For collaboration opportunities, please contact James M. Robinson, 301–761–7542; *James.Robinson4@nih.gov.*

Dated: March 28, 2017.

Suzanne Frisbie,

Deputy Director, Technology Transfer and Intellectual Property Office, National Institute of Allergy and Infectious Diseases.

[FR Doc. 2017–07058 Filed 4–7–17; 8:45 am]

BILLING CODE 4140–01–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

Office of the Director; Notice of Charter Renewal

In accordance with Title 41 of the U.S. Code of Federal Regulations, Section 102–3.65(a), notice is hereby given that the Charter for the Center for Scientific Review Advisory Council (CSRAC) was renewed for an additional two-year period on March 31, 2017.

It is determined that the CSRAC is in the public interest in connection with the performance of duties imposed on the National Institutes of Health by law, and that these duties can best be performed through the advice and counsel of this group.

Inquiries may be directed to Jennifer Spaeth, Director, Office of Federal Advisory Committee Policy, Office of the Director, National Institutes of Health, 6701 Democracy Boulevard, Suite 1000, Bethesda, Maryland 20892 (Mail Code 4875), Telephone (301) 496–2123, or *spaethj@od.nih.gov.*

Dated: April 4, 2017.

Michelle Trout,

Program Analyst, Office of Federal Advisory Committee Policy.

[FR Doc. 2017–07054 Filed 4–7–17; 8:45 am]

BILLING CODE 4140–01–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

National Heart, Lung, and Blood Institute; Notice of Meeting

Pursuant to section 10(a) of the Federal Advisory Committee Act, as amended (5 U.S.C. App.), notice is hereby given of a meeting of the Sleep Disorders Research Advisory Board.

The meeting will be open to the public, with attendance limited to space available. Individuals who plan to attend and need special assistance, such as sign language interpretation or other reasonable accommodations, should notify the Contact Person listed below in advance of the meeting.

Name of Committee: Sleep Disorders Research Advisory Board.

Date: June 22–23, 2017.

Time: June 22, 2017, 1:00 p.m. to 5:00 p.m.

Agenda: Update on NIH sleep disorders research programs and initiatives, updates on sleep related activities from selected Federal Agency partners, and discussion of the NIH Sleep Disorders Research Plan.

Place: National Institutes of Health, Two Rockledge Center, Conference Room 9100/9104, 6701 Rockledge Drive, Bethesda, MD 20892.

Time: June 23, 2017, 8:00 a.m. to 3:00 p.m.

Agenda: Discussion and updates on the NIH Sleep Disorders Research Plan, and potential directions for inter-agency coordination activities.

Place: National Institutes of Health, Two Rockledge Center, Conference Room 9100/9104, 6701 Rockledge Drive, Bethesda, MD 20892.

Contact Person: Michael J. Twery, Ph.D., Director, National Center on Sleep Disorders Research, Division of Lung Diseases, National Heart, Lung, and Blood Institute, National Institutes of Health, 6701 Rockledge Drive, Suite 10170, Bethesda, MD 20892–7952, 301–435–0199, *twerym@nhlbi.nih.gov.*

Information is also available on the Institute's/Center's home page: *https://www.nhlbi.nih.gov/about/committees/sdrab/,* where an agenda and any additional information for the meeting will be posted when available.

(Catalogue of Federal Domestic Assistance Program Nos. 93.233, National Center for Sleep Disorders Research; 93.837, Heart and Vascular Diseases Research; 93.838, Lung Diseases Research; 93.839, Blood Diseases and Resources Research, National Institutes of Health, HHS)

Dated: April 4, 2017.

Michelle Trout,

Program Analyst, Office of Federal Advisory Committee Policy.

[FR Doc. 2017–07056 Filed 4–7–17; 8:45 am]

BILLING CODE 4140–01–P